Roche’s test for Bordetella infections gains FDA clearance
December 3, 2025
The test, which runs on the cobas liat system, is said to deliver results in 15 minutes.
The test, which runs on the cobas liat system, is said to deliver results in 15 minutes.
The Vanquish device’s clinical data demonstrated an elimination of MRI visible intermediate risk disease in 91% of patients after a single procedure.
Eko Health announced today that the Centers for Medicare & Medicaid Services (CMS) has finalized national payment for its Sensora platform.
MannKind (Nasdaq:MNKD) announced that the FDA accepted a supplemental New Drug Application (sNDA) for its Furoscix ReadyFlow autoinjector.
The decision is supported by evidence from a clinical study and data from supporting analytical validation trials.
Medical Microinstruments (MMI) announced today that it won reimbursement for its surgical lymphovenous bypass (LVB) surgery system.
The a2z-Unified-Triage device is designed to simultaneously flag and prioritise seven urgent findings on abdomen-pelvis CT scans.
GE HealthCare’s Recon DL is claimed to be the first mammography technology to use deep learning alongside iterative reconstruction to improve image quality.
BD Surgiphor™ is a sterile, ready-to-use irrigation solution designed to help loosen and remove debris from surgical wounds during procedures
PRINCETON, N.J., Nov. 25, 2025 /PRNewswire/ — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that the U.S. Food and Drug Administration (FDA) has expanded the indication for the Bracco-branded Max 3™, a Rapid Exchange and Syringeless Injector for use in magnetic resonance imaging (MRI) procedures. In addition to single-dose and multi-dose vials, the Max 3™ system is now indicated for use with the newly approved VUEWAY® (gadopiclenol) injection Imaging Bulk Package (IBP) in 30 mL and 50 mL formats.